AstraZeneca: promising results for Tagrisso
(CercleFinance.com) - AstraZeneca reports that a phase III trial showed that Tagrisso (osimertinib), combined with chemotherapy, demonstrated a clinically and statistically significant improvement in progression-free survival (PFS) compared to Tagrisso alone, in patients with locally advanced (stage IIIB- IIIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFRm) mutation.
The laboratory states that at the time of this analysis, overall survival (OS) data was immature, however - therefore, it will be formally evaluated in a subsequent analysis.
In the meantime, these results [...] show that Tagrisso has the potential to provide patients with a new first-line treatment option that can extend their lives without their disease progressing, AstraZeneca said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The laboratory states that at the time of this analysis, overall survival (OS) data was immature, however - therefore, it will be formally evaluated in a subsequent analysis.
In the meantime, these results [...] show that Tagrisso has the potential to provide patients with a new first-line treatment option that can extend their lives without their disease progressing, AstraZeneca said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.